How should procurement teams evaluate connected versus non-connected injection devices?

Connected devices justify higher unit costs only when payer contracts reward adherence data or when the therapy demands real-time dose verification. For low-frequency, acute-use settings, non-connected options remain cost-optimal. Read More

What is the typical development timeline for a new combination product in this space?

From concept to regulatory clearance, most combination products require 4–6 years, with human-factors validation and stability testing consuming roughly 40% of that timeline [4]. Read More

Which polymer materials are replacing glass in injectable device containers?

Cyclic olefin copolymers and cyclic olefin polymers are the leading alternatives, offering break resistance, lower extractables, and compatibility with high-sensitivity biologics [13]. Read More

How do payer reimbursement models differ between hospital-administered and home-administered injectable therapies?

Hospital settings typically bill under facility-based codes at higher rates. At the same time, home-administered devices fall under pharmacy benefit or buy-and-bill models that reduce the total cost of care [5]. Read More

What role do contract device manufacturers play in the Injectable Drug Delivery Devices Market value chain?

Contract device manufacturers handle design-for-manufacturing, mold fabrication, and assembly for pharmaceutical sponsors lacking in-house device expertise, capturing an estimated 18–22% of platform-level revenue [6]. Read More

Are there specific regulatory barriers to entering the Asian injectable device market?

China's NMPA and India's CDSCO each require in-country clinical data for combination products, adding 12–24 months versus US or EU submission timelines [9]. Read More

How does the Injectable Drug Delivery Devices Market address sharps-disposal and environmental compliance?

Manufacturers increasingly embed integrated needle-retraction and safety-lock mechanisms, while several EU-based firms are piloting take-back programs aligned with extended-producer-responsibility regulations [17]. Read More

What is the current size of the injectable drug delivery devices market?

The injectable drug delivery devices market reached USD 808.00 billion in 2025 and is projected to reach USD 1,665.30 billion by 2035. Read More

What is the CAGR of the injectable drug delivery devices market?

The injectable drug delivery devices market is projected to grow at a CAGR of 7.50% during the forecast period 2026–2035. Read More

Which region leads the injectable drug delivery devices market?

North America holds the largest share at 45.80%, while Asia-Pacific is the fastest-growing region at 10.10% CAGR. Read More

What is driving growth in the injectable drug delivery devices market?

Growth in the injectable drug delivery devices market is primarily driven by an expanding biologics and biosimilar pipeline requiring parenteral delivery platforms, a global shift toward home-based self-administration, and rising chronic disease prevalence including diabetes and oncology indications. Read More

Injectable Drug Delivery Devices Market (2026 - 2035)

ID: MRFR/MED/0704-CR

164 Pages

Nidhi Mandole

Last Updated: June 30, 2026

Injectable drug delivery Market Research Report: Size, Share, Trend Analysis By Devices (Conventional Injection Devices, Self-Injection Devices), By Therapeutic Application (Autoimmune Diseases, Hormonal Disorders and Cancer) By Usage Pattern (Curative pattern, Immunization), By Site of Delivery (Intramuscular, Subcutaneous, Intra Dermal), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

Injectable Drug Delivery Devices Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)7.50%

2025 Market SizeUSD 808.00 Billion

2035 Market SizeUSD 1,665.30 Billion

Key Players

Baxter International Inc.

Gerresheimer AG

Terumo Corporation

West Pharmaceutical Services

Schott AG

Stevanato Group S.p.A.

Trends

Expanding Biologics and Biosimilar Pipeline
Shift to Home-Based Self-Administration
Rising Chronic-Disease Prevalence

Opportunities

AI-Enabled Smart Injectors and Adherence Platforms
Emerging-Market Expansion in Asia and Latin America
Data Monetization Through Connected-Device Ecosystems

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Expanding Biologics and Biosimilar Pipeline | |
  2. 3.1.2 Shift to Home-Based Self-Administration | |
  3. 3.1.3 Rising Chronic-Disease Prevalence | |
  4. 3.1.4 Connected and Digitalized Injection Devices | |
  5. 3.1.5 Biosimilar Interchangeability Designations | |
  6. 3.1.6 Regulatory Fast-Tracking for Combination Products | |
  7. 3.1.7 Patient-Centric Drug-Device Co-Development |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Stringent Regulatory Pathways for Combination Products | |
  2. 3.2.2 High Device Development and Tooling Costs | |
  3. 3.2.3 Reimbursement Variability Across Payer Systems | |
  4. 3.2.4 Needlestick Injury and Sharps-Disposal Concerns | |
  5. 3.2.5 Cold-Chain Logistics Complexity for Biologics |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 AI-Enabled Smart Injectors and Adherence Platforms | |
  2. 3.3.2 Emerging-Market Expansion in Asia and Latin America | |
  3. 3.3.3 Data Monetization Through Connected-Device Ecosystems | |
  4. 3.3.4 Subcutaneous Reformulation of Intravenous Therapies | |
  5. 3.3.5 Sustainable Device Design and Circular Manufacturing |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Injectable Drug Delivery Devices Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue Injectable Drug Delivery Devices Market — Table of Contents & Market Segmentation Executive Summary
1 Market Summary
2 Key Report Takeaways
3 Market Size and Forecast (2021–2035)
4 Driver Impact Analysis
5 Restraints Impact Analysis
6 Opportunities
7 Regional Market Share and Country-Level Analysis |
1. 7.1 North America |
2. 7.2 Europe |
3. 7.3 Asia-Pacific |
4. 7.4 South America |
5. 7.5 Middle East & Africa
8 Future Outlook (2026–2035)
9 Market Segmentation Analysis |
1. 5.1 By Device Type | |
  1. 5.1.1 Conventional Drug Delivery Devices | |
  2. 5.1.2 Advanced Drug Delivery Devices |
2. 5.2 By Therapeutic Application | |
  1. 5.2.1 Diabetes | |
  2. 5.2.2 Oncology | |
  3. 5.2.3 Autoimmune Disorders | |
  4. 5.2.4 Other Therapeutic Areas |
3. 5.3 By Usability | |
  1. 5.3.1 Disposable Injectors | |
  2. 5.3.2 Reusable Injectors |
4. 5.4 By Route of Administration | |
  1. 5.4.1 Subcutaneous | |
  2. 5.4.2 Intravenous | |
  3. 5.4.3 Intramuscular | |
  4. 5.4.4 Other Routes |
5. 5.5 By End User | |
  1. 5.5.1 Hospitals & Ambulatory Surgical Centres | |
  2. 5.5.2 Home-Care Settings | |
  3. 5.5.3 Specialty Clinics & Infusion Centres
10 Competitive Landscape
11 Recent News & Developments
12 Report Scope and Methodology
13 Detailed Sources and Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Injectable Drug Delivery Devices Market Summary Table |
TABLE 2 Injectable Drug Delivery Devices Market Market Size and Forecast, 2021–2035 |
TABLE 3 Driver Impact Analysis |
TABLE 4 Restraints Impact Analysis |
TABLE 5 Regional Market Share Summary |
TABLE 6 North America Country-Level Analysis |
TABLE 7 Europe Country-Level Analysis |
TABLE 8 Asia-Pacific Country-Level Analysis |
TABLE 9 South America Country-Level Analysis |
TABLE 10 Middle East & Africa Country-Level Analysis |
TABLE 11 Injectable Drug Delivery Devices Market Segmentation by Device Type |
TABLE 12 Injectable Drug Delivery Devices Market Segmentation by Therapeutic Application |
TABLE 13 Injectable Drug Delivery Devices Market Segmentation by Usability |
TABLE 14 Injectable Drug Delivery Devices Market Segmentation by Route of Administration |
TABLE 15 Injectable Drug Delivery Devices Market Segmentation by End User |
TABLE 16 Competitive Benchmarking Matrix |
TABLE 17 Report Scope and Methodology |
TABLE 18 Detailed Sources and Citations
16 LIST OF FIGURES |
FIGURE 1 Injectable Drug Delivery Devices Market Market Size Trend, 2021–2035 |
FIGURE 2 Injectable Drug Delivery Devices Market Year-over-Year Growth Outlook |
FIGURE 3 Regional Revenue Share Analysis |
FIGURE 4 Driver and Restraint Impact Matrix |
FIGURE 5 Competitive Landscape Snapshot |
FIGURE 6 Segment Share by Device Type |
FIGURE 7 Segment Share by Therapeutic Application |
FIGURE 8 Segment Share by Usability |
FIGURE 9 Segment Share by Route of Administration |
FIGURE 10 Segment Share by End User

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Device Type	Conventional Drug Delivery Devices, Advanced Drug Delivery Devices	Conventional Drug Delivery Devices	Advanced Drug Delivery Devices
By Therapeutic Application	Diabetes, Oncology, Autoimmune Disorders, Other Therapeutic Areas	Diabetes	Oncology
By Usability	Disposable Injectors, Reusable Injectors	Disposable Injectors	Reusable Injectors
By Route of Administration	Subcutaneous, Intravenous, Intramuscular, Other Routes	Subcutaneous	Intravenous
By End User	Hospitals & Ambulatory Surgical Centres, Home-Care Settings, Specialty Clinics & Infusion Centres	Hospitals & Ambulatory Surgical Centres	Home-Care Settings

Market Segmentation Overview

By Device Type

Sub-Segment	Key Trend
Conventional Drug Delivery Devices	Widespread utilization is sustained by the cost-efficiency, reliability, and high-volume clinical adoption of standard prefilled syringes.
Advanced Drug Delivery Devices	Demand is rapidly shifting toward smart autoinjectors and wearable patch pumps integrated with wireless connectivity for digital health monitoring.

Device Type segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Therapeutic Application

Sub-Segment	Key Trend
Diabetes	The segment is characterized by a major transition toward connected insulin pens and automated delivery systems that simplify patient self-management.
Oncology	Innovation is focused on specialized devices capable of safely administering highly viscous biologic therapies and monoclonal antibodies outside hospital settings.
Autoimmune Disorders	Product development heavily emphasizes ergonomic, low-force injection systems designed specifically for patients experiencing limited manual dexterity.
Other Therapeutic Areas	Growth is driven by the expansion of single-use, targeted delivery systems for emergency care, cardiovascular treatments, and reproductive health therapies.

Therapeutic Application, segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Usability

Sub-Segment	Key Trend
Disposable Injectors	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.
Reusable Injectors	Demand trend aligned with the RD segmentation analysis and regional adoption patterns.

Usability segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By Route of Administration

Sub-Segment	Key Trend
Subcutaneous	Adoption is growing rapidly due to the rising preference for self-administration and the expansion of biologic therapies.
Intravenous	Continuous demand is sustained by acute care settings requiring rapid drug onset and precise control over systemic medication delivery
Intramuscular	Innovation focuses on long-acting injectable formulations for antipsychotics and vaccines to improve overall patient compliance.
Other Routes	Specialized delivery systems are being developed to target localized therapies, such as intradermal vaccines and intraocular injections.

By Route of Administration segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

By End User

Sub-Segment	Key Trend
Hospitals & Ambulatory Surgical Centres	Institutional procurement centers on high-volume, standardized safety-engineered devices to minimize accidental needlestick injuries for healthcare workers.
Home-Care Settings	The shift toward decentralized healthcare accelerates the utilization of highly intuitive, ergonomic, and automated self-injection systems.
Specialty Clinics & Infusion Centres	Demand is driven by targeted outpatient infrastructure requiring complex administration setups for specialized biologic and oncology treatments.

By End User segmentation follows the same taxonomy used in Section 9 of the RD, keeping the TOC and segmentation add-on aligned with the generated report content.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”